Prof John Seymour

Professor John Seymour AM is a clinical haematologist and Associate Director of Clinical Research at the Peter MacCallum Centre, and the Director of the integrated Haematology Department of the Peter MacCallum Cancer Centre & the Royal Melbourne Hospital in Melbourne, Australia.

He received his MB, BS degrees from the University of Melbourne in 1987, completed a translational research fellowship at the MD Anderson Cancer Center in Houston, and subsequently received their Distinguished Alumnus award in 2011. He also completed PhD studies in the pathobiology of haematopoietic growth factors at the Ludwig Institute for Cancer Research. Professor Seymour is a member of several national and international scientific committees including, Cancer Australia Advisory Groups, the Scientific Advisory Committee for the International Conference on Malignant Lymphoma, Medical Advisory Board of the Lymphoma Coalition, and the Board of Directors of the International Extranodal Lymphoma Study Group.

He served for more than a decade as Executive member and Chairman of the major national clinical trials co-operative group in haematologic malignancies, the Australasian Leukaemia & Lymphoma Group. He is a frequent invited speaker nationally and internationally, is a member of numerous professional societies, an Editor-in-Chief of Leukemia & Lymphoma, and currently on the editorial boards of Blood and the British Journal of Haematology.

He has authored 18 book chapters, >500 peer reviewed publications (with >25,000 literature citations), and >700 conference abstracts. Actively involved in a broad range of collaborative research, Professor Seymour has been has been the principal investigator on >85 clinical trials and chief investigator on competitive grants awarded >AUD$18 million funding in the last 10 years. In 2015 he was awarded Membership of the Order of Australia, and elected to the Australian Academy of Health and Medical Sciences for his contributions to the field.

Conference highlights

'BT-199 (GDC-0199) in relapsed/refractory leukemia and small lymphocytic leukemia and lymphoma: high response rates among patients with high risk disease features including unmutated IGHV,'19th Congress of theEuropean Hematology Association,Tuesday 17 June 2014.

'Promising CLLtreatments: a Bcl-2inhibitorupdate',Patient Power, Friday 21 February 2014.

'DrJohn Seymour on the efficacy of ABT-199 in high-risk CLL',American Society of Hematology Annual Meeting and Exposition, Sunday 8 December 2013.